Lasolvan Rino nasal spray 82mkg / dose, 10ml

• Swelling of the nasal mucosa, nasal congestion caused by acute respiratory infections and / or hay fever (rhinitis, hay fever);

• sinusitis and otitis media (eustachitis), to facilitate the outflow of the contents of the paranasal sinuses, as recommended by a doctor.

Intranasally.

Adults and children over 6 years old: 1 injection in each nasal passage. Up to 4 injections per nasal passage per day.

Do not use the drug for more than 5-7 days without a doctor's prescription.

Instructions for using a bottle with a dispensing device

Before injection, the nasal passages should be cleaned.

1. Remove the protective cap.

2. Before the first use, it is necessary to make several injections into the air until a stable aerosol cloud appears.

The dispenser is then ready for use.

3. Keeping the head straight, insert the tip into the nasal passage and make one injection.

Repeat the procedure for the other nasal passage.

After removing the tip, inhale normally through the nose.

4. Put on the protective cap.

It is recommended to clean the handpiece after each use.

Nasal spray

1 dose

active substance:

tramazoline hydrochloride monohydrate (calculated as tramazoline hydrochloride) 82 mcg

excipients: citric acid monohydrate - 270 mcg; sodium hydroxide - 154 ?g; benzalkonium chloride - 14 ?g; hypromellose (hydroxypropyl methylcellulose) - 35 mcg; povidone - 2101 mcg; glycerol 85% - 700 mcg; magnesium sulfate heptahydrate - 49 mcg; magnesium chloride hexahydrate - 35 ?g; calcium chloride dihydrate - 11 ?g; sodium bicarbonate - 1 ?g; sodium chloride - 183 ?g; cineole (eucalyptol) - 7 mcg, L-menthol (levomenthol) - 14 mcg; racemic camphor - 14 ?g; purified water - 66358 mcg

hypersensitivity to tramazoline hydrochloride or benzalkonium hydrochloride, as well as other components of the drug;

angle-closure glaucoma;

atrophic rhinitis;

a history of operations on the skull performed through the nasal cavity;

children under 6 years of age.

With care: concomitant use of MAO inhibitors, tricyclic antidepressants, vasopressor and antihypertensive drugs; patients with arterial hypertension, heart disease, hyperthyroidism, prostatic hypertrophy, pheochromocytoma, porphyria - LasolvanЃ Rino should be used only on the recommendation of a doctor due to the potential risk of systemic absorption of the drug.

pharmachologic effect

The active substance of LazolvanЃ Rino is tramazoline hydrochloride, an alpha2-adrenergic agonist, which causes vasoconstriction. When applied to the mucous membranes of the nose due to the vasoconstrictor effect, the drug reduces swelling. As a result, the patency of the nasal passages is quickly restored, nasal breathing is facilitated for a long time.

The action of the drug begins within the first 5 minutes and lasts 8-10 hours.

Pharmacokinetics

Pharmacinetic studies have not been conducted in humans. The pharmacokinetics of tramazoline has been studied in rats, rabbits and monkeys. It has been shown that after administration of the drug inside or intranasally, 50-80% of the administered dose is absorbed. Tramazoline and its metabolites are distributed in all internal organs, the highest concentration is consistently found in the liver.

After oral or topical administration, the main metabolites are determined in the urine. T1 / 2 is from 5 to 7 hours.

Side effect

From the side of the nervous system: rarely - dizziness, disturbances in taste; infrequently - headache; frequency not established * - drowsiness, sedation.

From the side of the psyche: infrequently - anxiety; frequency not established * - hallucinations, insomnia.

From the side of the cardiovascular system: infrequently - palpitations; frequency not established * - arrhythmia, tachycardia, increased blood pressure.

Respiratory, chest and mediastinal disorders: often - nasal discomfort; infrequently (? 0.1% and <1%) - nasal edema, dry nose, rhinorrhea, sneezing; rarely - nosebleeds.

From the digestive system: infrequently - nausea.

Immune system disorders: frequency not established * - hypersensitivity.

Skin and subcutaneous tissue disorders *: frequency not established - rash, itching, skin edema.

Others: frequency not established - edema of the mucous membrane *, fatigue.

* Adverse events, the connection of which with the drug was regarded as possible, registered with the widespread use of the drug. The frequency of these rare events is difficult to assess.

** As symptoms of hypersensitivity.

Contraindications for use

• angle-closure glaucoma;

• atrophic rhinitis;

• operations on the skull, carried out through the nasal cavity (in history);

• children under 6 years of age;

• hypersensitivity to tramazoline hydrochloride or benzalkonium hydrochloride, as well as to other components of the drug.

Carefully:

For patients with arterial hypertension, heart disease, hyperthyroidism, diabetes mellitus, prostatic hyperplasia, pheochromocytoma, porphyria, the drug should be used only on the recommendation of a doctor due to the potential risk of systemic absorption of the drug.

Care should be taken when taking MAO inhibitors, tricyclic antidepressants, vasopressor drugs, and antihypertensive drugs.

Application during pregnancy and lactation

Long-term experience of use shows that LazolvanЃ Rino does not have a negative effect on pregnancy.

The drug should not be used in the first trimester of pregnancy. In later stages of pregnancy, the use of the drug LazolvanЃ Rino is allowed only after consulting a doctor.

The safety of using the drug LazolvanЃ Rino during breastfeeding has not been confirmed. The use of the drug during breastfeeding is allowed only after consulting a doctor.

Studies on the effect of LazolvanЃ Rino on fertility have not been conducted. Based on the available data, there is no mention of the possible effect of tramazoline hydrochloride on fertility.

Application in children

Contraindicated in children under 6 years of age.

special instructions

If, after 7 days of taking the drug, there are no positive dynamics of symptoms, it is necessary to decide whether to stop taking the drug or to continue treatment. Long-term use of nasal vasoconstrictor drugs can lead to the development of chronic inflammation and nasal congestion, as well as to atrophy of the nasal mucosa.

Avoid getting the drug in the eyes.

Influence on the ability to drive vehicles and mechanisms

Studies on the effect of the drug on the ability to drive a car and machinery have not been conducted. However, when taking the drug, such undesirable effects as hallucinations, drowsiness, sedation, dizziness and fatigue are possible. Therefore, care must be taken when driving and operating machinery.

If any of the above side effects occur, you should avoid performing potentially hazardous tasks such as driving and operating machinery.

Overdose

Symptoms: after an increase in blood pressure and tachycardia, it is possible (especially in children) a drop in blood pressure, the development of shock, reflex bradycardia, a decrease in body temperature.

By analogy with other alpha-sympathomimetics, the clinical picture of intoxication can be indistinct, since the phases of stimulation and depression of the central nervous system and the cardiovascular system can replace each other.

Especially in children, intoxication leads to effects on the central nervous system with the development of convulsions and coma, bradycardia, and respiratory depression. Symptoms of CNS stimulation are anxiety, agitation, hallucinations, and seizures. Symptoms of CNS depression include a decrease in body temperature, lethargy, drowsiness, and coma.

In addition, the following symptoms may develop: mydriasis, miosis, increased sweating, fever, pallor, cyanosis of the lips, dysfunctions of the cardiovascular system (including cardiac arrest); respiratory failure (including respiratory failure, respiratory arrest); psychological disorders.

Treatment: in case of nasal overdose, rinse or clear nose immediately. Symptomatic treatment may be required.

Drug interactions

Some antidepressants (MAO inhibitors and tricyclic antidepressants) and vasoconstrictor drugs, when administered simultaneously, can cause an increase in blood pressure.

Combined use with tricyclic antidepressants can lead to the development of arrhythmias.

Concomitant use with antihypertensive drugs (especially those that affect the sympathetic nervous system) can lead to various cardiovascular effects.